
Mainz enrols first subject in study to evaluate colorectal cancer test
Mainz Biomed has enrolled the first subject in its eAArly DETECT 2 feasibility study, aimed at evaluating the company’s colorectal cancer (CRC) test. This test integrates messenger ribonucleic acid (mRNA) biomarkers, an AI-developed algorithm, and a faecal …